Citation: | XU Wenjing, WANG Pei, MA Yueshi, GAO Liping. Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 375-380. DOI: 10.3971/j.issn.1000-8578.2021.20.0878 |
To investigate the clinical features and prognosis of HIV-negative plasmablastic lymphoma (PBL) patients.
We collected HIV-negative PBL cases reported in our hospital and other literatures from online databases from January 1, 1997 to March 30, 2020. The data of clinical features, molecular pathology, treatment and prognosis were summarized and analyzed.
We included 60 PBL patients, average age was 53.06±14.36 years, and most of them had relatively high Ann Arbor stage and Ki-67 expression. The average OS was 13.48±13.21 m. Kaplan-Meier curve revealed Ann Arbor stage, IPI index (3-5), B symptoms and CR in initial treatment were significantly related with patients' survival. Cox regression analysis indicated that the Ann Arbor stage and IPI index were the independent prognostic factors for patients' survival. Conclusion HIV-negative PBL mostly occurs in the middle-age and elderly patients, with advanced diagnosis stage and rapid tumor proliferation.
chemotherapy is the main treatment, while the therapeutic response and OS might be heterogeneous, the prognosis of most patients would be poor. The stage and IPI index are significantly related to the prognosis.
[1] |
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
|
[2] |
Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma[J]. Blood, 2015, 125(15): 2323-2330. doi: 10.1182/blood-2014-10-567479
|
[3] |
Reardon S. Infections reveal inequality between the sexes[J]. Nature, 2016, 54(7608): 447.
|
[4] |
Liu M, Liu B, Liu B, et al. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases[J]. Oncol Rep, 2015, 33(4): 1615-1620. doi: 10.3892/or.2015.3808
|
[5] |
蓝三春, 谢婧, 朱搏宇, 等. 乙型肝炎病毒相关浆母细胞淋巴瘤1例并文献复习[J]. 军事医学, 2018, 42(1): 77-78, 80. https://www.cnki.com.cn/Article/CJFDTOTAL-JSYX201801031.htm
Lan SC, Xie J, Zhu BY, et al. A case of hepatitis B virus-related plasmablastic lymphoma and literature review[J]. Jun Shi Yi Xue, 2018, 42(1): 77-78, 80. https://www.cnki.com.cn/Article/CJFDTOTAL-JSYX201801031.htm
|
[6] |
Sarode SC, Sarode GS, Patil A. Plasmablastic lymphoma of the oral cavity: a review[J]. Oral Oncol, 2010, 46(3): 146-153. doi: 10.1016/j.oraloncology.2009.12.009
|
[7] |
Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives[J]. Blood Lymphat Cancer, 2018, 8: 63-70. http://www.researchgate.net/publication/328072487_Plasmablastic_lymphoma_current_perspectives/download
|
[8] |
Bhatt R, Desai DS. Plasmablastic Lymphoma[M/OL]. StatPearls Publishing[2020-8-24]. https://www.ncbi.nlm.nih.gov/books/NBK532975/
|
[9] |
Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth[J]. Clin Lymphoma Myeloma Leuk, 2011, 11(2): 185-189. doi: 10.1016/j.clml.2011.03.008
|
[10] |
Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma[J]. Leuk Lymphoma, 2010, 51(11): 2047-2053. doi: 10.3109/10428194.2010.516040
|
[11] |
Akce M, Chang E, Haeri M, et al. Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma[J]. Case Rep Hematol, 2016, 2016: 3598547. http://www.ncbi.nlm.nih.gov/pubmed/27957358
|
[12] |
范舟, 李基炜, 易平勇, 等. 5例浆母细胞淋巴瘤临床病例分析和文献回顾[J]. 肿瘤药学, 2018, 8(1): 124-128. doi: 10.3969/j.issn.2095-1264.2018.01.29
Fan Z, Li JW, Yi PY, et al. Case Report on 5 Plasmablastic Lymphoma Patients and Literature Review by Retrospective Analysis[J]. Zhong Liu Yao Xue, 2018, 8(1): 124-128. doi: 10.3969/j.issn.2095-1264.2018.01.29
|
[13] |
Yan M, Dong Z, Zhao F, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab[J]. Eur J Haematol, 2014, 93(1): 77-80. doi: 10.1111/ejh.12286
|
[14] |
Holderness BM, Malhotra S, Levy NB, et al. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia[J]. J Clin Oncol, 2013, 31(12): e197-199. doi: 10.1200/JCO.2012.46.9593
|
[15] |
Pretscher D, Kalisch A, Wilhelm M, et al. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy[J]. Ann Hematol, 2017, 96(6): 967-970. doi: 10.1007/s00277-016-2904-7
|
[16] |
Mine S, Hishima T, Suganuma A, et al. Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets[J]. Sci Rep, 2017, 7(1): 10188. doi: 10.1038/s41598-017-10684-5
|
[17] |
Koenig G, Stevens TM, Peker D. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy[J]. Histopathology, 2015, 67(6): 930-932. doi: 10.1111/his.12718
|
[18] |
Yanamandra U, Sahu KK, Jain N, et al. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings[J]. Ann Hematol, 2016, 95(10): 1715-1717. doi: 10.1007/s00277-016-2732-9
|
[19] |
Laurent C, Fabiani B, Do C, et al. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients[J]. Haematologica, 2016, 101(8): 976-984. doi: 10.3324/haematol.2016.141978
|
[20] |
Cattaneo C, Finel H, McQuaker G, et al. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience[J]. Biol Blood Marrow Transplant, 2015, 21(6): 1146-1147. doi: 10.1016/j.bbmt.2015.03.008
|
[21] |
Elyamany G, Al Mussaed E, Alzahrani AM. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions[J]. Adv Hematol, 2015, 2015: 315289. http://www.ncbi.nlm.nih.gov/pubmed/27110244
|